ARVINAS, INC. Operating Cash Flow
ARVINAS, INC. (ARVN) reported Operating Cash Flow of -$117.50 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-04
- ARVINAS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$48.30M.
- ARVINAS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$69.20M.
- ARVINAS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$30.40M.
- ARVINAS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$59.10M.
- ARVINAS, INC. net cash provided by (used in) operating activities for fiscal 2025 was -$273.80M.
- ARVINAS, INC. net cash provided by (used in) operating activities for fiscal 2024 was -$259.30M.
- ARVINAS, INC. net cash provided by (used in) operating activities for fiscal 2023 was -$347.80M.
- ARVINAS, INC. net cash provided by (used in) operating activities for fiscal 2022 was -$273.50M, a 148.89% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 3 month as first filed | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 6 month as first filed | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 9 month as first filed | Net Cash Provided by (Used in) Operating Activities 12 month | Net Cash Provided by (Used in) Operating Activities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$48.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | -$117.50M 10-Q · filed 2026-08-04 | -$147.90M derived: sum of 3 quarters · filed 2026-08-04 | -$207.00M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2026-03-31 | -$69.20M 10-Q · filed 2026-05-11 | -$99.60M derived: sum of 2 quarters · filed 2026-05-11 | -$158.70M derived: sum of 3 quarters · filed 2026-05-11 | -$254.10M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-12-31 | -$30.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$89.50M derived: sum of 2 quarters · filed 2026-02-24 | -$184.90M derived: sum of 3 quarters · filed 2026-08-04 | -$273.80M 10-K · filed 2026-02-24 | ||||
| 2025-09-30 | -$59.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$154.50M derived: sum of 2 quarters · filed 2026-08-04 | -$243.40M 10-Q · filed 2025-11-05 | -$327.50M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-06-30 | -$95.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | -$184.30M 10-Q · filed 2026-08-04 | -$268.40M derived: sum of 3 quarters · filed 2026-08-04 | -$396.40M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-03-31 | -$88.90M 10-Q · filed 2026-05-11 | -$173.00M derived: sum of 2 quarters · filed 2026-05-11 | -$301.00M derived: sum of 3 quarters · filed 2026-05-11 | -$250.70M derived: sum of 4 quarters · filed 2026-05-11 | ||||
| 2024-12-31 | -$84.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$212.10M derived: sum of 2 quarters · filed 2026-02-24 | -$161.80M derived: sum of 3 quarters · filed 2026-02-24 | -$259.30M 10-K · filed 2026-02-24 | ||||
| 2024-09-30 | -$128.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$77.70M derived: sum of 2 quarters · filed 2025-11-05 | -$175.20M 10-Q · filed 2025-11-05 | -$258.30M derived: sum of 4 quarters · filed 2026-02-24 | ||||
| 2024-06-30 | $50.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$47.20M 10-Q · filed 2025-08-06 | -$130.30M derived: sum of 3 quarters · filed 2026-02-24 | -$215.10M derived: sum of 4 quarters · filed 2026-02-24 | ||||
| 2024-03-31 | -$97.50M 10-Q · filed 2025-05-01 | -$180.60M derived: sum of 2 quarters · filed 2026-02-24 | -$265.40M derived: sum of 3 quarters · filed 2026-02-24 | -$354.10M derived: sum of 4 quarters · filed 2026-02-24 | ||||
| 2023-12-31 | -$83.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$167.90M derived: sum of 2 quarters · filed 2026-02-24 | -$256.60M derived: sum of 3 quarters · filed 2026-02-24 | -$347.80M 10-K · filed 2026-02-24 | ||||
| 2023-09-30 | -$84.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-30 | -$173.50M derived: sum of 2 quarters · filed 2024-10-30 | -$264.70M 10-Q · filed 2024-10-30 | -$335.90M derived: sum of 4 quarters · filed 2025-02-11 | ||||
| 2023-06-30 | -$88.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-30 | -$179.90M 10-Q · filed 2024-07-30 | -$251.10M derived: sum of 3 quarters · filed 2025-02-11 | -$317.70M derived: sum of 4 quarters · filed 2025-02-11 | ||||
| 2023-03-31 | -$91.20M 10-Q · filed 2024-05-07 | -$162.40M derived: sum of 2 quarters · filed 2025-02-11 | -$229.00M derived: sum of 3 quarters · filed 2025-02-11 | -$307.60M derived: sum of 4 quarters · filed 2025-02-11 | ||||
| 2022-12-31 | -$71.20M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-11 | -$137.80M derived: sum of 2 quarters · filed 2025-02-11 | -$216.40M derived: sum of 3 quarters · filed 2025-02-11 | -$273.50M 10-K · filed 2025-02-11 | ||||
| 2022-09-30 | -$66.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$145.20M derived: sum of 2 quarters · filed 2023-11-07 | -$202.30M 10-Q · filed 2023-11-07 | -$238.00M derived: sum of 4 quarters · filed 2024-02-27 | ||||
| 2022-06-30 | -$78.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$135.70M 10-Q · filed 2023-08-08 | -$171.40M derived: sum of 3 quarters · filed 2024-02-27 | $510.10M derived: sum of 4 quarters · filed 2024-02-27 | ||||
| 2022-03-31 | -$57.10M 10-Q · filed 2023-05-05 | -$92.80M derived: sum of 2 quarters · filed 2024-02-27 | $588.70M derived: sum of 3 quarters · filed 2024-02-27 | $541.30M derived: sum of 4 quarters · filed 2024-02-27 | ||||
| 2021-12-31 | -$35.70M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $645.80M derived: sum of 2 quarters · filed 2024-02-27 | $598.40M derived: sum of 3 quarters · filed 2024-02-27 | $559.40M 10-K · filed 2024-02-27 | ||||
| 2021-09-30 | $681.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $634.10M derived: sum of 2 quarters · filed 2022-11-09 | $595.10M 10-Q · filed 2022-11-09 | $595.15M 10-Q · filed 2021-11-03 | $566.14M derived: sum of 4 quarters · filed 2023-02-23 | |||
| 2021-06-30 | -$47.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$86.40M 10-Q · filed 2022-08-04 | -$86.37M 10-Q · filed 2021-08-05 | -$115.36M derived: sum of 3 quarters · filed 2023-02-23 | -$137.75M derived: sum of 4 quarters · filed 2023-02-23 | |||
| 2021-03-31 | -$39.00M 10-Q · filed 2022-05-05 | -$38.97M 10-Q · filed 2021-05-04 | -$67.96M derived: sum of 2 quarters · filed 2023-02-23 | -$90.35M derived: sum of 3 quarters · filed 2023-02-23 | -$111.75M derived: sum of 4 quarters · filed 2023-02-23 | |||
| 2020-12-31 | -$28.96M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | -$51.35M derived: sum of 2 quarters · filed 2023-02-23 | -$72.75M derived: sum of 3 quarters · filed 2023-02-23 | -$89.70M 10-K · filed 2023-02-23 | -$89.76M 10-K · filed 2021-03-01 | |||
| 2020-09-30 | -$22.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | -$43.79M derived: sum of 2 quarters · filed 2021-11-03 | -$60.74M 10-Q · filed 2021-11-03 | -$76.89M derived: sum of 4 quarters · filed 2022-02-28 | ||||
| 2020-06-30 | -$21.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | -$38.35M 10-Q · filed 2021-08-05 | -$54.50M derived: sum of 3 quarters · filed 2022-02-28 | -$52.65M derived: sum of 4 quarters · filed 2022-02-28 | ||||
| 2020-03-31 | -$16.95M 10-Q · filed 2021-05-04 | -$33.10M derived: sum of 2 quarters · filed 2022-02-28 | -$31.25M derived: sum of 3 quarters · filed 2022-02-28 | -$44.82M derived: sum of 4 quarters · filed 2022-02-28 | ||||
| 2019-12-31 | -$16.15M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | -$14.30M derived: sum of 2 quarters · filed 2022-02-28 | -$27.87M derived: sum of 3 quarters · filed 2022-02-28 | -$40.60M 10-K · filed 2022-02-28 | -$40.63M 10-K · filed 2020-03-16 | |||
| 2019-09-30 | $1.85M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | -$11.72M derived: sum of 2 quarters · filed 2020-11-05 | -$24.45M 10-Q · filed 2020-11-05 | -$36.70M derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2019-06-30 | -$13.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-04 | -$26.30M 10-Q · filed 2020-08-04 | -$38.56M derived: sum of 3 quarters · filed 2021-03-01 | -$49.54M derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2019-03-31 | -$12.73M 10-Q · filed 2020-04-28 | -$24.99M derived: sum of 2 quarters · filed 2021-03-01 | -$35.97M derived: sum of 3 quarters · filed 2021-03-01 | -$48.15M derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2018-12-31 | -$12.25M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | -$23.24M derived: sum of 2 quarters · filed 2021-03-01 | -$35.42M derived: sum of 3 quarters · filed 2021-03-01 | -$16.12M 10-K · filed 2021-03-01 | ||||
| 2018-09-30 | -$10.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-04 | -$23.16M derived: sum of 2 quarters · filed 2019-11-04 | -$3.86M 10-Q · filed 2019-11-04 | $24.29M derived: sum of 4 quarters · filed 2019-11-04 | ||||
| 2018-06-30 | -$12.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-05 | $7.12M 10-Q · filed 2019-08-05 | $35.28M derived: sum of 3 quarters · filed 2019-08-05 | |||||
| 2018-03-31 | $19.30M 10-Q · filed 2019-05-09 | $47.46M derived: sum of 2 quarters · filed 2019-05-09 | ||||||
| 2017-12-31 | $28.16M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-26 | $5.11M 10-K · filed 2019-03-26 | ||||||
| 2017-09-30 | -$23.04M 10-Q · filed 2018-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |